ASXL1 and acquired polycythemia vera: ASXL1 mutations are associated with a worse prognosis in PV and PMF patients [48,57,58], and this unfavorable impact is not overcome by allogenic hematopoietic stem cell transplantation (allo-HSCT) [59].